Cytokinetics (CYTK) Equity Average (2016 - 2025)
Historic Equity Average for Cytokinetics (CYTK) over the last 13 years, with Q3 2024 value amounting to $47.3 million.
- Cytokinetics' Equity Average rose 11226.03% to $47.3 million in Q3 2024 from the same period last year, while for Sep 2024 it was $47.3 million, marking a year-over-year increase of 11226.03%. This contributed to the annual value of -$247.1 million for FY2023, which is 46349.82% down from last year.
- Latest data reveals that Cytokinetics reported Equity Average of $47.3 million as of Q3 2024, which was up 11226.03% from -$143.8 million recorded in Q2 2024.
- In the past 5 years, Cytokinetics' Equity Average registered a high of $246.4 million during Q4 2021, and its lowest value of -$412.6 million during Q4 2023.
- Its 5-year average for Equity Average is -$45.6 million, with a median of $35.8 million in 2020.
- The largest annual percentage gain for Cytokinetics' Equity Average in the last 5 years was 95369.08% (2020), contrasted with its biggest fall of 802276.9% (2020).
- Over the past 5 years, Cytokinetics' Equity Average (Quarter) stood at $131.5 million in 2020, then skyrocketed by 87.42% to $246.4 million in 2021, then crashed by 125.13% to -$61.9 million in 2022, then crashed by 566.08% to -$412.6 million in 2023, then skyrocketed by 111.47% to $47.3 million in 2024.
- Its last three reported values are $47.3 million in Q3 2024, -$143.8 million for Q2 2024, and -$391.2 million during Q1 2024.